Company intelligence / Profile preview
Avenzo Therapeutics
San Diego, California, United Statesavenzotx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
AVZO-021, the company's lead drug candidate, is currently in a Phase 1 study in the U.S. for the treatment of advanced solid tumors and in combinations in HR+/HER2-negative metastatic breast cancer[5][7].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Gilead Sciences (clinical trial partnership for combination treatment regimen)[6]Allorion Therapeutics (licensing agreement for AVZO-021)[10]VelaVigo (exclusive option agreement for Nectin4/TROP2 bispecific ADC)[7][9]
Beyond the preview
Go deeper on Avenzo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avenzo Therapeutics.